The synergy of a combined EZH2/ATM inhibition in BRCA1-deficient tumor cells could be demonstrated by using several small molecule inhibitors of EZH2 (GSK126, ZLD1039) and ATM (AZD1390, KU60019) that are currently at various stages of preclinical development. This evidence concerns the gene BRCA1 and neoplasm.